Nektar Therapeutics (NDAQ:NKTR) had its price target raised by Roth Capital from $23.00 to $31.00 in a research note issued on Monday. The firm presently has a “buy” rating on the stock.

Shares of Nektar Therapeutics (NDAQ:NKTR) traded up 42.65% during trading on Monday, hitting $22.11. 15,339,226 shares of the stock traded hands. The firm’s market cap is $3.40 billion. The company has a 50-day moving average of $13.78 and a 200-day moving average of $14.35. Nektar Therapeutics has a 52 week low of $11.41 and a 52 week high of $22.32.

Your IP Address:

Nektar Therapeutics Company Profile

Nektar Therapeutics is a biopharmaceutical company. The Company is engaged in the development of a pipeline of drug candidates that utilize its PEGylation and advanced polymer conjugate technology platforms, which are designed to enable the development of new molecular entities that target known mechanisms of action.

Receive News & Stock Ratings for Nektar Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nektar Therapeutics and related stocks with our FREE daily email newsletter.